The Federal Circuit has upheld a finding of the US Patent and Trademark Office, which rendered a Purdue Pharma oxycodone patent ineligible.
Medical device company Neovasc has added two co-inventors to three of its patents, settling a dispute with a competitor, Edwards Lifesciences.
Enzo Life Sciences has entered into a settlement and licensing agreement with pharmaceutical companies Hologic and Grifols, ending a patent dispute between the parties.
ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
The European Parliament has voted to approve the supplementary protection certificate manufacturing waiver, which will allow the stockpiling of generic versions of patented drugs.
Plans by Canada’s government to improve access to generic drugs could deter pharmaceutical companies from releasing brand medicine in the country, according to an internal government report.
The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.